Condition: Chronic Lymphocytic Leukemia (CLL) · Sponsor: AbbVie
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +/- X will be enrolled in the study in approximately 60 sites worldwide. Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Moores Cancer Center at UC San Diego /ID# 230157 | La Jolla, California, United States | Recruiting |
| Winship Cancer Institute of Emory University /ID# 230643 | Atlanta, Georgia, United States | Recruiting |
| Des Moines Oncology Research Association /ID# 232606 | Des Moines, Iowa, United States | Completed |
| Dana-Farber Cancer Institute /ID# 230061 | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Hospital /ID# 230268 | Detroit, Michigan, United States | Completed |
| St. Lukes Hospital of Duluth /ID# 250021 | Duluth, Minnesota, United States | Recruiting |
| Hattiesburg Clinic /ID# 233443 | Hattiesburg, Mississippi, United States | Recruiting |
| Summit Medical Group-Florham Park /ID# 244782 | Florham Park, New Jersey, United States | Completed |
| Regional Cancer Care Associates /ID# 244620 | Hackensack, New Jersey, United States | Recruiting |
| University of North Carolina /ID# 233313 | Chapel Hill, North Carolina, United States | Recruiting |
| Novant Health Presbyterian Medical Center /ID# 230201 | Charlotte, North Carolina, United States | Recruiting |
| Novant Health Forsyth Medical Center /ID# 249533 | Winston-Salem, North Carolina, United States | Recruiting |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04895436